Inclusion Criteria:

- ECOG performance status of 0 or 1

- Histologically confirmed breast cancer that overexpresses HER-2/NEU

- HER-2/NEU overexpression is defined as 3+ HER-2 positivity as measured by
immunohistochemistry OR HER-2 gene amplification as measured by FISH

- Evidence of metastatic disease and/or chest wall recurrence

- Evaluable (measurable or non-measurable) disease is allowed if confirmed within 4
weeks prior to study randomization

- No history or radiologic evidence of CNS disease

- Platelet count >= 100,000/mm^3

- Total bilirubin =< 1.5 mg/dL

- AST =< 2 times upper limit of normal (ULN) (=< 5 times normal in patients with known
liver involvement)

- Serum creatinine =< 1.5 mg/dL

- Urine protein:creatinine ratio =< 0.5 OR 24-hour urine protein < 1,000 mg

- INR =< 1.5 times ULN

- PTT =< 1.5 times ULN

- LVEF above the lower limit of normal by MUGA scan or ECHO

- No grade 2-4 neuropathy

- No unstable angina pectoris

- No serious cardiac arrhythmia requiring medication

- No clinically significant peripheral vascular disease

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No current non-healing wound or fracture

- No hypersensitivity to Chinese hamster ovary cell products or other recombinant human
antibodies, paclitaxel, or drugs using the vehicle Cremophor

- No serious medical or psychiatric illness that would preclude study participation

- No other active malignancy within the past 5 years except carcinoma in situ of the
cervix or nonmelanoma skin cancer

- Adjuvant or neoadjuvant taxane therapy for breast cancer is allowed provided last
dose was given >= 12 months prior to diagnosis of recurrence

- No prior chemotherapy, trastuzumab, or bevacizumab for metastatic breast cancer

- No prior cumulative dose of doxorubicin hydrochloride > 360 mg/m2 or epirubicin
hydrochloride > 640 mg/m2 (in the neoadjuvant or adjuvant setting)

- More than 4 weeks since prior major surgical procedure (except for non-operative
biopsy)

- More than 7 days since prior placement of a vascular access device

- Concurrent full-dose anticoagulants (e.g., warfarin) with PT/INR > 1.5 allowed
provided the following criteria are met:

- In-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or on a
stable dose of low molecular weight heparin

- No active bleeding or pathological condition that carries a high risk of bleeding
(e.g., tumor involving major vessels or known varices)

- No concurrent local radiotherapy for pain control or life-threatening situations

- No concurrent drugs known to inhibit platelet function, including the following:

- dipyridamole,

- ticlopidine,

- clopidogrel,

- cilostazol

- Adjuvant trastuzumab (Herceptin) therapy for breast cancer is allowed provided last
dose was given >= 12 months prior to diagnosis of recurrence

- Adjuvant or neoadjuvant therapy with lapatinib ditosylate is allowed provided last
dose was given >= 4 weeks prior to diagnosis of recurrence

- Absolute neutrophil count >= 1,000/mm^3

- No clinically significant cardiovascular disease

- No cerebrovascular accident within the past 6 months

- No myocardial infarction or unstable angina within the past 6 months

- No New York Heart Association class II-IV congestive heart failure

- No uncontrolled hypertension

- Endocrine treatment in the adjuvant or metastatic setting is allowed, provided last
dose given >= 2 weeks prior to randomization

- More than 3 weeks since prior radiotherapy